Patent intelligence · US
US 8431124
Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)
Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)
Patent details — US 8431124
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 30, 2013
- Expiration
- Apr 25, 2033
- Applicant
- HALOZYME, INC.
- Claims
- 21
- CPC classes
- A61K, A61K2039/505, A61K38/00, A61K38/47
Quick answer
US 8431124 (Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)) is held by HALOZYME, INC.. Status: granted. Granted Apr 30, 2013. Expires Apr 25, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- HALOZYME, INC.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K2039/505, A61K38/00, A61K38/47, A61K39/395, A61K9/0048
More from HALOZYME, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12421308
Anti-G-CSF antibodies and uses thereof
granted -
US 12371685
PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof
granted -
US 12264345
PH20 polypeptide variants, formulations and uses thereof
granted -
US 12195773
PH20 polypeptide variants, formulations and uses thereof
granted -
US 12178860
Hyaluronidase enzyme formulations for high volume administration
granted -
US 12152262
PH20 polypeptide variants, formulations and uses thereof
granted -
US 12123035
PH20 polypeptide variants, formulations and uses thereof
granted -
US 12110520
PH20 polypeptide variants, formulations and uses thereof
granted
Frequently asked questions
What is US patent 8431124?
US 8431124 (Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)) is held by HALOZYME, INC.. Status: granted. Granted Apr 30, 2013. Expires Apr 25, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8431124?
HALOZYME, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 70 pharmaceutical patents for this assignee.
When does US 8431124 expire?
Our index shows an expiration date of Apr 25, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.